The volatility trade that powered CME Group's first quarter cooled in the second, and the exchange's core fee engine went into reverse. Clearing and transaction fees fell to $1,352.5 million from $1,388.0 million a year earlier, a 2.6% decline, as aggregate average daily volume slipped 1% to 29.8 million contracts and the average fee earned per contract dropped to $0.678 from $0.690 — and that rate decline would have been worse without a clearing and transaction fee increase that took effect on April 1, 2026. The swing from the first quarter is stark: those same fees had risen 15.4% year over year in the first three months of 2026, to $1,542.6 million from $1,337.3 million. Total revenue still edged up 0.8% to $1,706.2 million, because market data and information services jumped 20.2% to a record $238.1 million and other revenue added $9.7 million — together more than covering the $35.5 million fee shortfall. Net income rose 1.6% to $1,041.8 million, but that increase came entirely from below the tax line: pre-tax income actually slipped 0.2% to $1,327.7 million. The quarter is best read as a live test of whether CME's non-transaction revenue can hold the line when trading activity normalizes, and the answer for now is a qualified yes.
All figures are taken from CME Group's Form 10-Q for the quarter ended June 30, 2026 and the company's July 22, 2026 earnings release unless otherwise noted.
1. Consolidated Balance Sheet
1-1. Principal asset items
One structural point comes first. CME's balance sheet is dominated by $158,110.7 million of performance bonds and guaranty fund contributions — collateral that clearing members post to secure their positions. It appears as both an asset and an identical liability, so it inflates the balance sheet without belonging to shareholders. Stripping it out, total assets were $36,565.9 million at June 30, 2026, down 5.7% from $38,768.1 million at December 31, 2025.
| Item | Dec 31, 2025 ($M) | Jun 30, 2026 ($M) | Change % |
|---|---|---|---|
| Cash and cash equivalents | 4,416.9 | 2,144.2 | -51.5 |
| Marketable securities | 125.0 | 131.4 | +5.1 |
| Accounts receivable, net | 639.2 | 753.1 | +17.8 |
| Property, net | 362.7 | 351.2 | -3.2 |
| Intangible assets — trading products | 17,175.3 | 17,175.3 | 0.0 |
| Intangible assets — other, net | 2,610.7 | 2,494.6 | -4.4 |
| Goodwill | 10,514.7 | 10,505.8 | -0.1 |
The cash halving is the headline movement, and it is a capital-return story rather than an operating one. CME paid $3,165.7 million in dividends and $1,236.9 million in buybacks during the first half against $2,207.0 million of operating cash flow, drawing down the cash pile it had built through 2025. Receivables grew 17.8% while half-year revenue grew 7.6%, which is worth watching but is consistent with a strong June quarter of billings rather than collection trouble.
More than 80% of the shareholder-relevant asset base is intangible — $30,175.7 million of the $36,565.9 million total. Trading products carry $17,175.3 million and are not amortized at all: these are the futures and options franchises acquired with CBOT, NYMEX and the Kansas City Board of Trade, and their designations as regulated contract markets carry no term limits. Goodwill adds $10,505.8 million. Trading products did not move a dollar this half, and goodwill slipped only $8.9 million on currency translation — meaning no impairment was recorded on either. Under US GAAP these sit at historical cost and cannot be revalued upward, so the reported book value understates what a modern replacement of these franchises would cost. Operating leases for corporate offices run up to 12 years and are immaterial alongside these balances.
1-2. Debt structure — financial versus operating liabilities
Excluding the collateral pass-through, total liabilities were $10,045.5 million, essentially unchanged from $10,039.9 million at year-end. Financial debt is $3,424.2 million, all of it fixed-rate senior notes, versus $3,422.3 million six months earlier — no new issuance, no repayment in the half.
The maturity ladder is unusually comfortable. Of $3,450.0 million in par value, nothing matures before June 2028, only that $500.0 million note (14.5%) comes due within three years, and $2,200.0 million sits beyond 2031 — $750.0 million due 2032, $750.0 million due 2043 and $700.0 million due 2048. Stated coupons range from 2.65% to 5.30%, a weighted average of roughly 4.1%; the 2043 notes are swapped to an effective 4.73%. With every note fixed, a higher-rate environment does not reprice this stack — CME carries legacy debt that is below current issuance cost on average until the 2028 note matures. Interest paid in the half was $70.2 million. Undrawn capacity is substantial: a $2.3 billion revolving credit facility maturing April 2030 with no borrowings outstanding, plus a separate $7.0 billion 364-day secured facility reserved for clearing house liquidity emergencies.
Operating liabilities are small and stable: accounts payable $68.0 million, other current liabilities $538.6 million, other liabilities $793.8 million. Deferred tax liabilities of $5,220.9 million are the larger item, and they arise mainly from the acquired intangibles rather than from operations. Contract liabilities — cash billed before revenue is earned — rose to $52.8 million from $16.7 million, reflecting upfront annual market data licenses.
1-3. Capital structure
Total shareholders' equity fell 7.7% to $26,520.4 million from $28,728.2 million. Retained earnings dropped 15.2% to $5,457.5 million, and the walk is exact: $6,433.2 million opening, plus $2,196.1 million of net income, less $3,171.8 million of dividends declared (the $3,165.7 million in the cash flow statement is cash actually paid). Paid-in capital and common stock fell to $21,008.0 million from $22,213.1 million, driven by $1,236.9 million of share repurchases charged directly against capital — CME retires repurchased shares rather than holding treasury stock.
Two structural changes deserve note. All 4,584 thousand Series G preferred shares converted into Class A common during the half, removing the preferred layer entirely. And the buyback pace changed character: 4,384,776 shares repurchased at an average $280.87 in the first half of 2026 — $1.2 billion excluding excise tax, $1,236.9 million including it — against just 32,265 shares in the same period of 2025. Second-quarter repurchases alone were $695 million at an average $273.14, alongside roughly $468 million of dividends. The conversion and the buyback roughly offset each other on share count, which ended at 359,275 thousand versus 358,950 thousand at year-end. Authorization remaining under the December 2024 program is $1.5 billion.
Accumulated other comprehensive income slipped to $54.9 million from $81.9 million, almost entirely on foreign currency translation of $23.5 million after tax. There are no meaningful unrealized investment losses buried here.
2. Consolidated Statement of Income
2-1. Core earnings metrics
| Item | Q2 2025 ($M) | Q2 2026 ($M) | H1 2025 ($M) | H1 2026 ($M) |
|---|---|---|---|---|
| Total revenues | 1,692.0 | 1,706.2 | 3,334.3 | 3,586.3 |
| Clearing and transaction fees | 1,388.0 | 1,352.5 | 2,725.3 | 2,895.1 |
| Market data and information services | 198.1 | 238.1 | 392.6 | 462.2 |
| Other revenue | 105.9 | 115.6 | 216.4 | 229.0 |
| Total expenses | 562.7 | 599.1 | 1,097.0 | 1,169.5 |
| Operating income | 1,129.3 | 1,107.1 | 2,237.3 | 2,416.8 |
| Operating margin (%) | 66.7 | 64.9 | 67.1 | 67.4 |
| Income before income taxes | 1,330.3 | 1,327.7 | 2,575.1 | 2,838.6 |
| Net income | 1,025.1 | 1,041.8 | 1,981.3 | 2,196.1 |
| Net margin (%) | 60.6 | 61.1 | 59.4 | 61.2 |
| Diluted EPS ($) | 2.81 | 2.88 | 5.43 | 6.06 |
The quarter and the half tell opposite stories, and both are true. In the second quarter, revenue rose 0.8% while operating income fell 2.0% — operating leverage worked in reverse, with every 1% of revenue growth producing roughly 2.3% of operating income decline. Operating margin gave up 1.8 percentage points to 64.9%. Across the full half, revenue rose 7.6% and operating income rose 8.0%, so margin edged up to 67.4% and leverage was mildly positive.
The bridge between the two is volatility. Management attributes the first-quarter surge to Middle East geopolitical conflict that disrupted energy supply and pushed participants into precious metals, and states plainly that volatility "subsided relative to periods of very high volatility earlier in the year" during the second quarter. Half-year average daily volume rose 10% to 33.0 million contracts; second-quarter volume fell 1% to 29.8 million.
Below the operating line the picture is more mixed than the net income line suggests. Total non-operating income rose 9.8% to $220.6 million in the quarter, contributing 16.6% of pre-tax income — but that improvement was not enough to offset the $22.2 million operating decline, so pre-tax income fell 0.2% to $1,327.7 million. The entire 1.6% increase in net income came from the effective tax rate, which fell to 21.5% from 22.9% on favorable state tax examination settlements — a one-time benefit that should not be extrapolated. Adjusting the quarter to the prior-year 22.9% rate would put net income near $1,023.0 million, slightly below the prior year rather than up 1.6%. Within non-operating income, the composition also matters: gross earnings on reinvested collateral actually fell 6% to $1,388.8 million on a lower average rate of return, but the offsetting distribution back to clearing firms fell faster (down 8% to $1,265.7 million), so CME's retained net spread widened to $123.1 million from $113.1 million. Equity in earnings of unconsolidated subsidiaries went the other way, dipping on the sale of the OSTTRA joint venture in the fourth quarter of 2025.
On CME's own adjusted basis, the quarter reads better: excluding $56.0 million of purchased-intangible amortization, $12.4 million of deferred compensation, $6.0 million of restructuring and severance, $2.9 million of litigation settlements and $1.0 million of transaction costs — plus related tax effects — adjusted operating income was $1,185.0 million and adjusted diluted EPS $2.99 against GAAP's $2.88. Readers should note that the adjusted figure does not undo the tax settlement benefit described above.
Diluted EPS rose 2.5% to $2.88 against 1.6% net income growth. The gap is the preferred conversion, not the buyback: a year earlier $5.7 million of Series G preferred dividends and $7.2 million of undistributed earnings allocated to the preferred cut net income attributable to common shareholders to $1,012.2 million in the second quarter of 2025; with the preferred fully converted into Class A common on March 5, 2026, no such deduction applied in 2026. That $12.9 million release lifted the earnings base for EPS purposes, making diluted EPS growth outrun headline net income growth. Diluted shares actually edged up 0.26% to 361,282 thousand from 360,355 thousand — share repurchases were a modest headwind to EPS, not a tailwind.
2-2. Fixed versus variable cost structure
| Expense line | Q2 2025 ($M) | Q2 2026 ($M) | Change % |
|---|---|---|---|
| Compensation and benefits | 221.6 | 233.5 | +5.4 |
| Technology | 70.9 | 83.3 | +17.5 |
| Professional fees and outside services | 37.4 | 29.1 | -22.2 |
| Amortization of purchased intangibles | 56.1 | 56.0 | -0.2 |
| Depreciation and amortization | 27.3 | 28.2 | +3.3 |
| Licensing and other fee agreements | 96.2 | 109.1 | +13.4 |
| Other | 53.2 | 59.9 | +12.6 |
| Total expenses | 562.7 | 599.1 | +6.5 |
Roughly two-thirds of the cost base is fixed. Compensation, technology, depreciation and intangible amortization together were $401.0 million, or 66.9% of total expenses, and none of it flexes with volume in a single quarter. That is why a 1% volume decline translated into margin compression.
The compensation line needs a caveat, though. Salaries, benefits and employer taxes were essentially flat in the quarter, down $0.3 million. The 5.4% increase came from a $4.7 million rise in the non-qualified deferred compensation liability — which management notes has no effect on net income because an equal and offsetting change runs through investment income — and $4.1 million of higher stock-based compensation on performance awards. Only the latter is a real economic cost.
Licensing and other fee agreements — payments to index owners such as S&P and Nasdaq — is the genuinely variable line, and at $109.1 million it rose 13.4% because, in management's words, of "record volumes for certain equity products" even as overall volume fell. Management quantifies license fees as $12.9 million of the $36.4 million quarterly expense increase. Technology support services added $11.6 million, driven by an ongoing Google Cloud transformation project. That is discretionary investment spending, not run-rate inflation, though it will persist until the project completes. Rent expense added a further $9.4 million, against a prior-year period that carried gains on lease contractions. Working the other way, legal fees fell $6.2 million as the class action litigation that ran through mid-2025 wound down, and currency fluctuation swung $3.3 million favorably. The "Other" line's 12.6% rise absorbs $6.0 million of restructuring and severance and $2.9 million of litigation settlements — costs CME itself treats as non-recurring.
3. Consolidated Statement of Cash Flows
| Item | H1 2025 ($M) | H1 2026 ($M) | Change |
|---|---|---|---|
| Operating cash flow | 2,175.1 | 2,207.0 | +1.5% |
| Investing cash flow | (34.0) | (52.4) | wider |
| Financing cash flow | 40,210.6 | (5,974.8) | reversal |
| Cash and cash equivalents, period end | 1,981.3 | 2,144.2 | +8.2% |
The financing line needs unpacking before it misleads. Movements in clearing member collateral run through financing activities: an inflow of $43,262.5 million in the first half of 2025 versus an outflow of $1,545.4 million in 2026. That is customer money moving in and out of the clearing house, not CME's own funding. Excluding it, financing cash flow was an outflow of $4,429.4 million this half against $3,051.9 million last year — a 45% increase in capital returned, driven almost entirely by buybacks. The prior-year figure also contained the only debt activity of either period: $742.3 million of proceeds against a $750.0 million repayment in 2025, versus nothing in 2026.
Free cash flow, defined as operating cash flow less capital expenditure of $45.4 million, was $2,161.6 million versus $2,142.5 million a year earlier. Capital intensity is negligible at 1.3% of revenue, and the spending is maintenance in character — CME has no factories to build. This is a business that converts revenue to cash with very little reinvestment drag.
Earnings quality is clean but slightly weaker. Operating cash flow was 1.005 times net income in the first half of 2026, down from 1.098 times a year earlier. Two items explain most of the compression, and neither is an accounting red flag: receivables absorbed $113.9 million of cash as June billings grew, and income taxes paid rose to $689.7 million from $579.6 million, a $110.1 million cash outflow that lags the reported tax benefit discussed above. Management itself attributes the modest 1.5% increase in operating cash flow to higher trading volume and higher interest earned on reinvested collateral, net of distributions.
4. What to watch
The investment case now rests on a specific question rather than a general one. In the first quarter, a 15.4% jump in transaction fees carried everything; in the second, with volume down 1%, the non-transaction lines had to carry the quarter and just managed it — total revenue up 0.8%, pre-tax income down 0.2%, and reported net income growth manufactured entirely by a tax settlement that will not repeat. Three things determine whether the qualified yes hardens into an unqualified one: whether market data can compound off a record $238.1 million base rather than lapping a one-time repricing; whether the retained spread on collateral holds as the Federal Reserve cuts, since the gross earnings line already fell 6% this quarter; and whether the Google Cloud program and rising licensing fees stop outrunning revenue once volumes normalize. The fixed-cost base that produces a 67% margin in a boom is the same base that produces margin compression in a flat quarter — and the second quarter of 2026 was the first look at what that costs.